Rayvio_News_Filter
$HOWL 🏥
Werewolf Therapeutics, Inc. presented Phase 1/1b and Phase 1b/2 clinical data at SITC 2026 showing WTX-124 and WTX-330 were well tolerated and demonstrated antitumor activity, and it aligned with FDA on an 18 mg IV Q2W Phase 2 dose for WTX-124.
Market-relevant event
4

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Farticles%2Fmain%2Fd7%2F2114.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Farticles%2Fmain%2Ff5%2F284.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault22.jpg)